Hemab Therapeutics Holdings, Inc. (COAG)
| Market Cap | 1.12B |
| Revenue (ttm) | n/a |
| Net Income | -63.91M |
| EPS | -67.56 |
| Shares Out | 44.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,905 |
| Open | 30.87 |
| Previous Close | 34.00 |
| Day's Range | 24.94 - 32.00 |
| 52-Week Range | 24.94 - 36.61 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About COAG
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann... [Read more]
News
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagin...
Hemab Therapeutics Holdings IPO Registration Document (S-1)
Hemab Therapeutics Holdings has filed to go public with an IPO on the NASDAQ